Formulary
Mirikizumab: Indications, Dosing, Side Effects and Interactions
Mirikizumab is a humanised monoclonal antibody that selectively binds to cytokine interleukin-23 (IL-23) and inhibits the release of pro-inflammatory cytokines.
MedNext Academy | 3 min read
Mirikizumab: Indications, Dosing, Side Effects and Interactions
Mirikizumab is a humanised monoclonal antibody that selectively binds to cytokine interleukin-23 (IL-23) and inhibits the release of pro-inflammatory cytokines.
Drug action
Mirikizumab is a humanised monoclonal antibody that selectively binds to cytokine interleukin-23 (IL-23) and inhibits the release of pro-inflammatory cytokines.
Cautions
Chronic infection; history of recurrent infection Cautions, further information Risk of infection Patients must be screened for tuberculosis before starting treatment. Consider anti-tuberculosis therapy before initiation of mirikizumab in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. M Patients should be brought up to date with current immunisation schedule before initiating treatment. M
Contraindications
Active infection
Side effects
Common or very common With parenteral use Arthralgia; headache; increased risk of infection; oropharyngeal complaints; skin reactions Uncommon With intravenous use Infusion related hypersensitivity reaction Frequency not known With parenteral use Drug-induced liver injury; hypersensitivity
Interactions
**Other interactions (2):**
- In clinical studies, concomitant use of corticosteroids or oral immunomodulators did not influence the safety of mirikizumab.
- Population pharmacokinetic data analyses indicated that the clearance of mirikizumab was not impacted by concomitant administration of 5ASAs (5aminosalicylic acid), corticosteroids or oral...
Pregnancy
Avoid (limited information available). M
Breast feeding
Specialist sources indicate use with caution, especially if breast-feeding a neonate or preterm infant (no information available). Large molecular weight suggests limited excretion into milk and drug molecule likely to be partially destroyed in the infant's gastro-intestinal tract; waiting for at least 2 weeks postpartum to resume treatment may minimise transfer to infant.
Medicinal forms
Solution,Solution
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Mirikizumab in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

